Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2nd season was awesome, right? I love Kevin Spacey!
Have Menon and Ehrlich take selfies;)
Beautiful summation. A joy to read. Thank you!
Cuz he wanted to fly the coop!
Soligenix Enters into a $10 Million Equity Purchase Agreement
PRINCETON, N.J., Aug. 3, 2015 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC. Brean Capital, LLC served as financial advisor for this transaction.
Soligenix has agreed to file a registration statement with the U.S. Securities and Exchange Commission ("SEC") covering the resale of the shares of common stock that will be issued to the investors under the terms of the equity purchase agreement. Once the SEC has declared the registration statement effective, Soligenix will have the right, at its sole discretion, to sell up to $10 million worth of common stock under the terms set forth in the agreement. Proceeds from this transaction will be used to fund the company's ongoing development initiatives of its late-stage product candidates, including its pivotal Phase 3 clinical study of SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL).
"We are very excited to receive this commitment for the capital infusion led by Kodiak Capital and look forward to having the participating funds as valued investors. The commitment serves as a vote of confidence in our ability to advance our late-stage clinical programs and increase shareholder value," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix.
Ryan Hodson, Managing Director of Kodiak Capital, said, "We have been following Soligenix through its development progress for some time and are very pleased to be making this investment. We are impressed with the Company's technologies and management's ability to execute on their development and regulatory strategies. We look forward to partnering with Soligenix as a long-term, fundamental investor."
News
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
CEO stated:
“The new funds, the exchange of Series A and C warrants, as well as the previously announced conversion of subordinated debt to equity, were arranged to position the company [for the second quarter of 2015] to both have stockholders’ equity in excess of the minimum stockholders’ equity of $2.5 million—as required by NASDAQ as one option for meeting the continued listing standards — and to have positive working capital.”
Guess that makes it official. Delisting is no longer an issue! Think I may be a RGSE long now. Psyched to see what this CEO can do.
End of the day wall to keep it in check. IMO. Anybody else feel like "they" are keeping it from running. Slow unwinding of a massive short position before the big run? Just speculating.
Remember 1.6 million of the OS is owned and locked down by one group. I think they're called Riverside something something. Can't remember exact name.
Another poster contacted the company last week and said Its 12 million and change. Still a very low float IMO.
Compliments of moonshine1999
NASDAQ compliance: According to the 8K the company did the recent offering to meet the alternative listing requirement of having 2.5 mil in shareholder equity. If we aren't compliant now, which I feel we are, we still have until October to be and any uptick in PPS will not only raise the market cap faster with the higher OS count, but will also raise that equity amount.
About RGS Energy
RGS Energy (RGSE) is one of the nation's leading rooftop installers of solar equipment, serving residential and small business customers in the mainland U.S. and Hawaii. Beginning with one of the very first photovoltaic panels sold in 1978, the company has installed tens of thousands solar power systems. RGS Energy makes it very convenient for customers to save on their energy bill by providing a comprehensive solar solution, from design, financing, permitting and installation to ongoing monitoring, maintenance and support.
RGS Energy Sets Second Quarter 2015 Conference Call for Monday, August 10, 2015 at 4:30 p.m. ET
Agreed. Thanks for finding out.
I believe the 90+ million is pre split and it's now around 10+ post warrants. Could be 12 mill but I'm 99% sure it's no way near 90. That needs to be fixed. I hope you get an answer back and I hope the company will get the word out immediately.
I thought the OS was only 10 million and change. Please correct me if I'm wrong.
If people want an end of the day Rally. Release the Monkey!!!
Nice volume as accumulation continues. Overdue for some news IMO.
What we need right now is the Monkey. Did Rally sleep in?
I think if we get news next week we could still get a short squeeze. When a stock is heavily shorted as this was it can take a long time to unwind slowly. Which I believe is what's happening here. IMO.
Hah! Rally and Sally. Love those monkeys!!
This stock was so heavily shorted on the way down. Anyone think these last two weeks have been a period of quiet covering of short positions?
One day down four to go. Could we be on the NASDAQ Wednesday/Thursday next week?
Seems like Solar's down today across the board. For now when oil goes down so does solar. Investors being ignant. Two different markets. We wait on news. GL
If only the askholes would get out of the way. People want in IMO. Move it up fools!
Longer term will be much greater IMO. This is a turnaround story. Glad they got out of the way for now. Nothing stalls a run like the 10%ers. I get it. Trying to make a living but sometimes you need to get out of the way and let it run. Especially when there's this kind of volume. GLTA
Looks like the traders who need to make their ??% off the lows won't get out of the way. IMO. So short sighted. Volume is there. Need to eat through them. Get out of the way fools!
From the same Zacks article.
"Based on our analysis, we think Soligenix shares are undervalued at current market price. Currently shares of Soligenix are trading at around $1.90 per share, which values the Company at $49 million in market cap based on 26 million outstanding shares. This deeply undervalues Soligenix shares in our view".
Hang tight. Based on the warrant dates, This should be the Last day of this.
SNGX: ThermoVax™ Addresses Critical Concerns for Industry and Government
By Grant Zeng, CFA
OBB:SNGX
Soligenix (SNGX) is a late-stage development biopharmaceutical company focused on cancer supportive care, GI disorders as well as biodefense. The Company holds three platform technologies: the SGX94 IDR (Innate Defense Regulator) platform, the oral BDP platform and ThermoVax platform. Based on these technologies, Soligenix has built a diversified pipeline with potential to target multiple indications.
Etc. etc. go look it up...
News out at 10am
I agree 100%. Only problem is I keep buying and it keeps going down! Is there a bottom? Lol! Good times...
What is an SS restriction and why does it end tomorrow PM? Thanks
http://www.usnews.com/news/business/articles/2015/06/30/oxycontin-maker-bows-out-of-meeting-on-harder-to-abuse-drug
OxyContin Maker Bows Out of Meeting on Harder-to-Abuse Drug
OxyContin maker drops out of FDA meeting to review newer, abuse-deterrent tablet.
Associated Press June 30, 2015 | 3:47 p.m. EDT + More
http://www.usnews.com/dims4/USNEWS/1ab17d2/2147483647/thumbnail/150x100%3E/quality/85/?url=%2Fcmsmedia%2Fa4%2F4a853fc5fefcf0845c1a9ac58570c9%2F6977FE_PR_080923associatedpress.jpg
By MATTHEW PERRONE, AP Health Writer
WASHINGTON (AP) — The makers of the potent painkiller OxyContin have pulled out of a federal meeting to review the company's harder-to-abuse version of the much-debated drug.
An executive for Purdue Pharma says the company wants more time to review and analyze its data. As a result, the company has withdrawn its application that was slated to be reviewed before a Food and Drug Administration committee next week.
"Given the complexity of epidemiological research and the unprecedented nature of this exercise, we've made the decision to complete additional analyses," said Dr. Richard Fanelli, the company's head of regulatory affairs, in an emailed statement
FDA meetings are typically planned months in advance and cancellations are highly unusual. The agency must present detailed evaluations of the company's application and coordinate travel for outside experts who advise the federal government.
OxyContin was re-formulated in 2010 to discourage patients from crushing the tablets for snorting or injection. Purdue Pharma discontinued the older version of its blockbuster drug, which was long associated with problems of addiction, overdose and death.
Next week's two-day meeting was intended to evaluate whether those abuse-deterrent features actually translate into reduced rates of abuse by pain patients.
The FDA required Stamford, Connecticut-based Purdue Pharma to conduct long-term, follow-up studies tracking rates of abuse, addiction, overdose and death with the updated drug.
The FDA has been urging companies to design new painkillers with tamper-resistant features to make them more difficult to abuse. Deaths linked to opioid pain medications like OxyContin and Vicodin have quadrupled since 1999 to an estimated 16,000 in 2013, the most recent year for which the Centers for Disease Control and Prevention reports figures.
Doctors prescribe these co-called opioids for a wide range of ailments, from post-surgical pain to arthritis and migraines. Medical experts continue to disagree over the appropriate role of the drugs, with some arguing that they should only be used for the most severe cases, such as cancer pain or end-of-life care.
OxyContin was the first in a class of long-acting opioids designed to deliver around-the-clock pain relief. The pills and tablets are formulated to slowly release their drug contents over 12 or more hours. But abusers often try to get a massive, heroin-like high by releasing the entire dose at once via chewing, snorting or injecting crushed tablets' contents.
Purdue Pharma's harder-to-abuse version of OxyContin can still be abused if chewed or simply swallowed.
This guy said this a couple of post ago. He doesn't even know the market is closed tomorrow!
"Can see a green day but can also test 1$ tomorrow".
Nice call when I asked about upcoming catalyst!
"Possible 8k saying the offering is complete. That would be really good. Send the shorts covering fast".
Glad I added at the end of the day! Thanks Mooonshine1999!!!
Definitely willing to give it time. Just seems like there's unlimited amount of shares people are willing to sell. At a loss no less because RGSE I think haven't seen these prices. Going long for the turnaround. Want to buy more. GL
Hah ha not funny! Well kinda funny. But quotes like these make that scenario seem unlikely.
"In addition to eliminating our subordinated debt and improving our working capital, the conversion of this debt held by Riverside, our largest shareholder and whose director is our chairman, demonstrates their confidence in our turn-around progress and plans," said Dennis Lacey, president and CEO of RGS Energy.
I thought it was 1 for 20.
True. Hope so. I've been patiently waiting for entry and I thought I did good getting in yesterday. Guess I need to just buy more. Just hesitant because tomorrow could be worst.